Choline Availability and the Synthesis of Acetylcholine

  • D. R. Haubrich
  • N. H. Gerber
  • A. B. Pflueger
  • W. J. Pouch
Part of the Advances in Behavioral Biology book series (ABBI, volume 25)


Most of the work on transmitter replacement therapy by means of precursor loading has been directed toward manipulation of neurotransmitters synthesized from aromatic amino acids (47). However, beginning in the mid 1970’s, clinical investigators became interested in the use of choline (Ch) to treat disorders in which too little acetylcholine (ACh) was formed in the brain, or in which the formation of an excess of the neurotransmitter was believed to be desirable. This interest in Ch as a therapeutic agent was triggered by basic research showing that the administration of Ch to laboratory animals could cause an increase in the level of ACh in the brain, a phenomenon first described in 1972 by Kuntscherova (32). Although the beneficial effects of Ch in some disorders such as tardive dyskinesia (see 2) may reside in other properties of the molecule (e.g. a direct postsynaptic muscarinic action of Ch has been demonstrated (9,20,31)), there is evidence that part of the effect of Ch is elicited through stimulation of ACh synthesis and release. This evidence is reviewed in the first part of this report.


Tardive Dyskinesia Cholinergic Neuron Homovanillic Acid Corpus Striatum Dopamine Metabolism 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Aquilonius, S.M. and Eckernas, S.A. (1975): New Eng. J. Med. 293:1105–1106.Google Scholar
  2. 2.
    Barbeau, A., Growdon5 J.H. and Wurtman, R.J. (eds) (1979): Nutrition and the Brain, Vol. 5, Raven Press, New York.Google Scholar
  3. 3.
    Bernheim, F. and Bernheim, M.C.C. (1938): Amer. J. Physiol. 121:55–60.Google Scholar
  4. 4.
    Birks, R. and MacIntosh, F.C. (1961): Canad. J. Biochem. Physiol. 39:787–827.CrossRefGoogle Scholar
  5. 5.
    Bowers, M.B. Jr. (1967): Life Sci. 6: 1927–1933.CrossRefGoogle Scholar
  6. 6.
    Brown, L. and Feldberg, W. (1936): J. Physiol. 88:265–283.Google Scholar
  7. 7.
    Carlsson, A. and Lindqvist, M. (1973): J. Neural. Trans. 34: 79–91.CrossRefGoogle Scholar
  8. 8.
    Cohen, E.L. and Wurtman, R.J. (1975): Life Sci. 16:1095–1102.CrossRefGoogle Scholar
  9. 9.
    Consolo, S., Ladinsky, H. and Gomeni, R. (1979): Pharmacol. Res. Comm. 11:903–918.CrossRefGoogle Scholar
  10. 10.
    Davis, K.L., Hollister, L.E., Barchas, J.D. and Berger, P. A.(1976): Life Sci. 19: 1507–1516.CrossRefGoogle Scholar
  11. 11.
    DeLaHuerga, J. and Popper, H. (1951): J. Clin. Invest. 30: 463–470.CrossRefGoogle Scholar
  12. 12.
    Eckernas, S.A. (1977): Acta Physiol. Scand. 449 (Suppl.).Google Scholar
  13. 13.
    Flentge, F. and Vanderberg5 C.J. (1979): J. Neurochem. 32: 1331–1333.CrossRefGoogle Scholar
  14. 14.
    Friesen, A.J.D., Ling, G.M. and Nagai, M. (1967): Nature 214: 722–724.CrossRefGoogle Scholar
  15. 15.
    Growdon, J.H., Hirsch, M.J., Wurtman, R.J. and Weiner, W.(1977):New Eng. J. Med. 297:524–527.CrossRefGoogle Scholar
  16. 16.
    Haubrich, D.R. (1973): J. Neurochem. 21:315–328.CrossRefGoogle Scholar
  17. 17.
    Haubrich, D.R. and Chippendale, T.J. (1977): Life Sci. 20: 1465–1478.CrossRefGoogle Scholar
  18. 18.
    Haubrich, D.R. and Goldberg, M.E. (1975): Neuropharmacology 14:211–214.CrossRefGoogle Scholar
  19. 19.
    Haubrich, D.R. and Pflueger, A.B. (1979): Life Sci. 24: 1083–1090.CrossRefGoogle Scholar
  20. 20.
    Haubrich, D.R., Risley, E.A. and Williams, M. (1979): Biochem. Pharmacol. 28:3673–3674.CrossRefGoogle Scholar
  21. 21.
    Haubrich, D.R. and Wang, P.F.L. (1976): Biochem. Pharmacol. 25: 669–672.CrossRefGoogle Scholar
  22. 22.
    Haubrich, D.R., Wang, P.F.L., Clody, D.E. and Wedeking, P.W. (1975): 17:975–980.Google Scholar
  23. 23.
    Haubrich, D.R., Wang, P.F.L., Herman, R.L. and Clody, D.E. (1975): Life Sci. 17:739–748.CrossRefGoogle Scholar
  24. 24.
    Haubrich, D.R., Wang, P.F.L. and Wedeking, P. (1974): Fed. Proc. 33:477.Google Scholar
  25. 25.
    Haubrich, D.R., Wang, P.F.W, and Wedeking, P.W. (1975): J. Pharmacol. Exp. Ther. 193:246–255.Google Scholar
  26. 26.
    Haubrich, D.R., Wedeking, P.W. and Wang, P.F.L. (1974): Life Sci. 14:921–927.CrossRefGoogle Scholar
  27. 27.
    Hebb, C. (1972): Physiol. Rev. 52:918–957.Google Scholar
  28. 28.
    Hirsch, M.J., Growdon, J.H. and Wurtman, R.J. (1977): Brain Res. 125:383–385.CrossRefGoogle Scholar
  29. 29.
    Hollister, L.E., Jenden, D.J., Amaral, J.R.D., Barchas, J.D., Davis, K.L. and Berger, P.A. (1978): Life Sci. 22:17–22.CrossRefGoogle Scholar
  30. 30.
    Krell, R.D. and Goldberg, A.M. (1975): Biochem. Pharmacol. 24:. 391–396.CrossRefGoogle Scholar
  31. 31.
    Krnjevic, K. and Reinhardt, W. (1979): Science 206: 1321–1323.CrossRefGoogle Scholar
  32. 32.
    Kuntscherova, J. (1972): Physiol. Bohem. 21: 655–660.Google Scholar
  33. 33.
    London, E.D. and Coyle, J.T. (1978): Biochem. Pharmacol. 27: 2962–2965.CrossRefGoogle Scholar
  34. 34.
    Mann, P.J.G. and Quastel, J.H. (1937): Biochem. J. 31: 869–878.Google Scholar
  35. 35.
    Neill, A.R., Grime, D.W. and Dawson, R.M.C. (1978): 170: 529–535Google Scholar
  36. 36.
    Pedata, F., Wieraszko, A. and Pepeu, G. (1977): Pharmacol. Res. Comm. 9: 755–761.CrossRefGoogle Scholar
  37. 37.
    Racagni, G., Trabucchi, M. and Cheney, D.L. (1975): N.-S. Arch. Pharmacol. 290: 99–105.CrossRefGoogle Scholar
  38. 38.
    Re., O. (1974): Curr. Ther. Res. 16: 1238–1242.Google Scholar
  39. 39.
    Sethy, V.H., Kuhar, M.J., Roth, R.H., Van Woert, M.H. and Aghajanian, G.K. (1973): 55:481–484.Google Scholar
  40. 40.
    Smith, J.C., Cavallito, C.J. and Foldes, F.F. (1967): Biochem. Pharmacol. 16:2438–2441.CrossRefGoogle Scholar
  41. 41.
    Ulus, I.H. and Wurtman, R.J. (1976): Science 194:1060–1061.CrossRefGoogle Scholar
  42. 42.
    Wecker, L. and Dettbarn, W.D. (1979): J. Neurochem. 32.:961–967.CrossRefGoogle Scholar
  43. 43.
    Wecker, L., Dettbarn, W.D. and Schmidt, D. (1978): Science 199:86–87.CrossRefGoogle Scholar
  44. 44.
    Wecker, L. and Schmidt, D.E. (1978): Soc. Neurosci. Abst. 4:436Google Scholar
  45. 45.
    White, H.L. and Wu, J.C. (1973): J. Neurochem. 20:297–307.CrossRefGoogle Scholar
  46. 46.
    Wittenberg, J. and Kornberg, A. (1953): J. -Biol. Chem. 202: 431–444.Google Scholar
  47. 47.
    Wurtman, R.J. (1979): IN Nutrition and the Brain, Vol. 5 (eds) A. Barbeau, J.H. Growdon and R.J. Wurtman, Raven Press, New York, pp. 1–12Google Scholar

Copyright information

© Plenum Press, New York 1981

Authors and Affiliations

  • D. R. Haubrich
    • 1
  • N. H. Gerber
    • 1
  • A. B. Pflueger
    • 1
  • W. J. Pouch
    • 1
  1. 1.Department of Pharmacology Neuropsychopharmacology SectionMerck Institute for Therapeutic ResearchWest PointUSA

Personalised recommendations